Alpine Woods Capital Investors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Alpine Woods Capital Investors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,000	Closed	-$655K	–	227
2021 Q4	$655K	Hold	5,000	–	–	0.06%	162
2021 Q3	$612K	Hold	5,000	–	–	0.07%	173
2021 Q2	$570K	Hold	5,000	–	–	0.06%	176
2021 Q1	$601K	Hold	5,000	–	–	0.07%	176
2020 Q4	$508K	Hold	5,000	–	–	0.06%	179
2020 Q3	$387K	Hold	5,000	–	–	0.06%	201
2020 Q2	$557K	Buy	+5,000	New	+$435K	0.11%	171

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Alpine Woods Capital Investors's KRTX Position: Q1 2022 in Review

Alpine Woods Capital Investors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022, closing a stake of 5,000 shares — an estimated $655K sold.

Alpine Woods Capital Investors first reported a position in KRTX in Q2 2020 and held it in 7 quarters. The position peaked at $655K in Q4 2021. 177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

Alpine Woods Capital Investors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Alpine Woods Capital Investors sold 5,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $655K.
Alpine Woods Capital Investors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Alpine Woods Capital Investors's Karuna Therapeutics, Inc. Common Stock position peaked at $655K in Q4 2021.
177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2022, filed 10 May 2022.